Navigation Links
Steri-Cath® Closed Ventilation Single Lumen Suction Systems

ProductsSteri-Cath® Closed Ventilation Single Lumen Suction Systems
Company Portex
Item Steri-Cath® Closed Ventilation Single Lumen Suction Systems
Features 
  • The distal tip has a soft, 15° bevel with smooth lateral eyes
  • The thumb valve allows simple on-off manipulation of the suction source, and its raised edges reduces the risk of the valve being inadvertently activated
  • A lightweight, clear T-piece connects the patients endotracheal or tracheostomy tube with the breathing circuit, allowing suctioning during mechanical ventilation without circuit disconnection
  • 20 units per case
Description Steri-Cath® systems are available with a single lumen or dual lumen catheter. Full kits contain a swivel, MDI adapter.

Trac-Wedge™ device, and patient label with day-of-the-week stickers. Economy kits include a patient label. Dual swivel elbow kits do not include the MDI adapter. All Portex® Steri-Cath® systems are latex-free.

Steri-Cath® suction systems are designed for airway suctioning of critically ill patients on ventilatory support.

Steri-Cath® systems reduce the risk of contamination by isolating clinician contact with the catheter. The systems help reduce oxygen desaturation by allowing constant patient ventilation. These systems are cost effective and easy to use.

Steri-Cath® Systems Feature the Calibrated Maxi-Flo® Catheter.
Info Portex
Customer Service: (603) 352-3812
Web site: http://www.smiths-medical.com

Related medicine products :

1. Steri-Cath® Closed Ventilation Economy Suction Systems
2. Lacrimal Cannula, Straight - Closed End.
3. Lacrimal Cannula, Curved - Closed End.
4. Small Joint Closed Curette
5. Comfor™ Cast Boot - Rocker Sole - Closed Toe
6. Vibratome 900 R Closed Loop Water System
7. Silicone Foley - Closed End
8. 4.8 Fr Closed Tip Ureteral Stents
9. Classic Closed Tip Ureteral Stents
10. Double-J® II Closed Tip Ureteral Stents
11. Double-J® Closed Tip Ureteral Stents
Breaking Medicine Technology:Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 2AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 3China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3Haemonetics Sets Date for First Quarter Fiscal Year 2010 Earnings Release 3A August 3 2009 51439 1Varian Medical Systems Management to Present at the Piper Jaffray Cancer Summit 51436 1Medical Imaging Modality Vendors Should Focus on Innovation and Alliances with Market Leaders Advises Frost 26 Sullivan 51431 1Medical Imaging Modality Vendors Should Focus on Innovation and Alliances with Market Leaders Advises Frost 26 Sullivan 51431 2Medical Imaging Modality Vendors Should Focus on Innovation and Alliances with Market Leaders Advises Frost 26 Sullivan 51431 3